Fallopian Tube Neoplasms: all 734 studies

Page 4 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.

• Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00429793Phase 2Results posted
• A Study of Chemotherapy Treatment for Patients With Ovarian CancerCompletedNCT00428610Phase 2Results posted
• A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse TreatmentCompletedNCT00421889Phase 1/2Results posted
• Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian CarcinomaTerminatedNCT00418093Phase 2Results posted
• Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedNCT00408070Phase 2Results posted
• Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")CompletedNCT00391118Phase 2Results posted
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00388037Phase 2Results posted
• Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic CancerCompletedNCT00381888Phase 2Results posted
• Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerTerminatedNCT00373217Phase 2Results posted
• Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity CancerTerminatedNCT00354601Phase 2Results posted
• Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn CancersCompletedNCT00343044Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00334893Phase 2Results posted
• Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00331422Phase 2Results posted
• Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian CancerTerminatedNCT00322881Phase 2Results posted
• Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyCompletedNCT00318370Phase 2Results posted
• Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00317772Phase 1/2Results posted
• Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative MedicineCompletedNCT00293293Not applicableResults posted
• A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian CancerCompletedNCT00281632Phase 2Results posted
• Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00278343Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00275028Phase 2Results posted
• Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT00267696Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for CancerCompletedNCT00245050Phase 3Results posted
• An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior ChemotherapyCompletedNCT00191646Phase 3Results posted
• Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerCompletedNCT00182767Phase 1/2Results posted
• GM-CSF, Sargramostim in Women With Recurrent Ovarian CancerCompletedNCT00157573Phase 2Results posted
• Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00114166Phase 2Results posted
• Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00112957Phase 2Results posted
• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerStatus unknownNCT00108745Phase 3Results posted
• A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00096993Phase 2Results posted
• Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096200Phase 2Results posted
• Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00066729Phase 1Results posted
• Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaCompletedNCT00059787Phase 2Results posted
• Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00041080Phase 3Results posted
• S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian CancerCompletedNCT00008138Phase 2Results posted
• S9912 Combination Chemo in Stage III Ovarian Cancer,CompletedNCT00003896Phase 2Results posted
• Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian CancerCompletedNCT07648745Phase 2
• Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel ChemotherapyCompletedNCT07154966
• Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer TreatmentCompletedNCT06870539
• Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT06834672Phase 3
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsTerminatedNCT06714617Phase 1
• Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerActive, not recruitingNCT06619236Phase 3
• A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian CancerWithdrawnNCT06545617Phase 1/2
• Diet, Hepcidin, and Chemotherapy RDIActive, not recruitingNCT06483997
• Nudge to Gynecologic OncologyActive, not recruitingNCT06451263Not applicable
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerActive, not recruitingNCT06342986Phase 1
• NM32-2668 in Adult Patients With Selected Advanced Solid TumorsTerminatedNCT06299163Phase 1
• Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA StudyCompletedNCT06274541
• Choices About Genetic Testing And Learning Your Risk With Smart TechnologyCompletedNCT06184867Not applicable
• RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerCompletedNCT06173037Phase 2
• A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT06087289Phase 1/2
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedNCT06007586Phase 3
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• A Biomarker Screening Protocol for Participants With Solid TumorsTerminatedNCT05891197
• REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1TerminatedNCT05870748Phase 2/3
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• A Study of CDX-585 in Patients With Advanced MalignanciesCompletedNCT05788484Phase 1
• Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant ChemotherapyActive, not recruitingNCT05763199Phase 2
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian CancerWithdrawnNCT05672095Phase 1/2
• Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous CarcinomaStatus unknownNCT05665023Phase 2
• A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian CancerStatus unknownNCT05622890Phase 3
• AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian CancerActive, not recruitingNCT05617755Phase 1
• Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerActive, not recruitingNCT05605535Phase 2
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryTerminatedNCT05538624Phase 1/2
• First in Human Study of IMGN151 in Recurrent Gynaecological CancersActive, not recruitingNCT05527184Phase 1
• PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT05465941Phase 2
• Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingNCT05456685Phase 2
• ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingNCT05446298Phase 2
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT05415709Early Phase 1
• Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerActive, not recruitingNCT05406674Phase 2
• ITIL-306 in Advanced Solid TumorsTerminatedNCT05397093Phase 1
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnNCT05368506Early Phase 1
• A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2
• Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)TerminatedNCT05329545Phase 3
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• A Study to Investigate LYL797 in Adults With Solid TumorsTerminatedNCT05274451Phase 1
• KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients with Ovarian CancerCompletedNCT05256576Not applicable
• Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological CancerActive, not recruitingNCT05220033Not applicable
• A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerTerminatedNCT05200364Phase 1
• A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesActive, not recruitingNCT05199272Phase 1/2
• A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
• Tempus Priority Study: A Pan-tumor Observational StudyActive, not recruitingNCT05179824
• Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2
• Using Aspirin to Improve Immunological Features of Ovarian TumorsSuspendedNCT05080946Early Phase 1
• Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT05047926Not applicable
• A Study of Navicixizumab in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT05043402Phase 3
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube CancerCompletedNCT04991051
• Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCStatus unknownNCT04983550Phase 2
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal CancerStatus unknownNCT04846842Phase 2
• A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedNCT04814875Phase 1/2
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2

← Fallopian Tube Neoplasms overview